Lecankitug vs sonelokimab
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Psoriasis
Shared mechanism: IL-17A/F · full Psoriasis pipeline
Lecankitug
Marketed by Livzon Pharmaceutical Group Inc. and partners
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
No aligned efficacy figure on record for this race.
sonelokimab
Developed by MoonLake Immunotherapeutics under a licence from Merck KGaA
NCT03384745 · Phase 2 · completed
This was a well-powered, randomized, blinded, placebo-controlled trial using a validated skin-clearance measure as its primary endpoint, and every sonelokimab dose group achieved a substantially and statistically significantly higher clear/almost-clear skin rate than placebo at week 12.
Reported efficacy
Number of Participants With an Investigator's Global Assessment (IGA) Score of 0 or 1 (Week 12, as compared to Week 0 (baseline)): Primary endpoint, IGA 0/1 at week 12: placebo 0.0%, sonelokimab 30mg 48.1% (p<0.0001), 60mg 84.6% (p<0.0001), 120mg normal load 77.4% (p<0.0001), 120mg augmented load 88.2% (p<0.0001), secukinumab 300mg (active reference) 77.4% (p<0.0001) vs placebo. (met)
Result source: NCT03384745
Results for Psoriasis
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Lecankitug | sonelokimab |
|---|---|---|
| PASI 75 | —Not posted · NCT07746479 | 84.9% vs 90.6%vs SecukinumabNCT033847453 other results
|
| PASI 90 | —Not posted · NCT07746479 | 69.8% vs 64.2%vs SecukinumabNCT033847453 other results
|
| PASI 100 | —Not posted · NCT07746479 | 37.7% vs 28.3%vs SecukinumabNCT033847453 other results
|
| sPGA 0/1 | —Not posted · NCT07746479 | —Not reported |
| DLQI, change | —Not posted · NCT07746479 | —Not reported |
PASI 75
- Lecankitug
- —Not posted · NCT07746479
- sonelokimab
- 84.9% vs 90.6%vs SecukinumabNCT03384745
3 other results
- 90.2% vs 90.6% NCT03384745
- 88.5% vs 90.6% NCT03384745
- 65.4% vs 90.6% NCT03384745
PASI 90
- Lecankitug
- —Not posted · NCT07746479
- sonelokimab
- 69.8% vs 64.2%vs SecukinumabNCT03384745
3 other results
- 76.5% vs 64.2% NCT03384745
- 65.4% vs 64.2% NCT03384745
- 36.5% vs 64.2% NCT03384745
PASI 100
- Lecankitug
- —Not posted · NCT07746479
- sonelokimab
- 37.7% vs 28.3%vs SecukinumabNCT03384745
3 other results
- 33.3% vs 28.3% NCT03384745
- 25% vs 28.3% NCT03384745
- 17.3% vs 28.3% NCT03384745
sPGA 0/1
- Lecankitug
- —Not posted · NCT07746479
- sonelokimab
- —Not reported
DLQI, change
- Lecankitug
- —Not posted · NCT07746479
- sonelokimab
- —Not reported
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Lecankitug: no structured comparison results are available for Psoriasis.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. Lecankitug: 0 of 4 rows · sonelokimab: 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | sonelokimab |
|---|---|
| Dropout rate | —120 mga NCT03384745 · Phase 2 show 7 more results—120 mg NCT03384745 · Phase 2 5.7%120 mg NCT03384745 · Phase 2 3.9%120 mg NCT03384745 · Phase 2 —60 mg NCT03384745 · Phase 2 1.9%60 mg NCT03384745 · Phase 2 0%30 mg NCT03384745 · Phase 2 —30 mg NCT03384745 · Phase 2 |
| Discontinued due to AEs | —120 mga NCT03384745 · Phase 2 show 7 more results—120 mg NCT03384745 · Phase 2 1.9%120 mg NCT03384745 · Phase 2 3.9%120 mg NCT03384745 · Phase 2 —60 mg NCT03384745 · Phase 2 0%60 mg NCT03384745 · Phase 2 0%30 mg NCT03384745 · Phase 2 —30 mg NCT03384745 · Phase 2 |
| Serious AEs | 2%120 mga NCT03384745 · Phase 2 show 7 more results1.9%120 mg NCT03384745 · Phase 2 —120 mg NCT03384745 · Phase 2 —120 mg NCT03384745 · Phase 2 1.9%60 mg NCT03384745 · Phase 2 —60 mg NCT03384745 · Phase 2 —30 mg NCT03384745 · Phase 2 3.8%30 mg NCT03384745 · Phase 2 |
| Most frequent reported AEs | 120 mga nasopharyngitis 7.8% (placebo 7.7%) pruritus 7.8% (placebo 3.8%) oral candidiasis 5.9% (placebo 0%) NCT03384745 · Phase 2 show 3 more results120 mg nasopharyngitis 17% (placebo 7.7%) headache 5.7% (placebo 1.9%) pruritus 5.7% (placebo 3.8%) NCT03384745 · Phase 2 60 mg nasopharyngitis 21.2% (placebo 7.7%) pruritus 7.7% (placebo 3.8%) headache 5.8% (placebo 1.9%) NCT03384745 · Phase 2 30 mg nasopharyngitis 7.7% (placebo 7.7%) arthralgia 5.8% (placebo 1.9%) hypertension 5.8% (placebo 3.8%) NCT03384745 · Phase 2 |
Notes
- aPopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
sonelokimab
show 3 more results
show 3 more results
show 3 more results
show 3 more results
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Lecankitug's landscape · sonelokimab's landscape